American Red Cross, Medical & Scientific Office, Rockville, Maryland, USA.
Division of High-Consequence Pathogens and Pathology, US Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, Georgia, USA.
Transfusion. 2024 Jun;64(6):980-985. doi: 10.1111/trf.17837. Epub 2024 Apr 22.
For many years, there has been concern about the risk of transmission of classic forms of Creutzfeldt-Jakob disease (CJD) by blood transfusion, particularly after the recognition of such transmission of variant CJD (vCJD). We report on a 28-year lookback study of recipients of blood from donors who subsequently developed CJD.
Patients with diagnosed CJD and a history of blood donation were identified. Blood centers were asked to provide information about the distribution of the donations and consignees were requested to provide information about the recipients of the donations. Vital status of each available recipient was determined and, if deceased, the reported cause(s) of death were obtained primarily from the National Death Index. All recipients included in the study database contributed person-time up to the last recorded review of vital status.
There were 84 eligible donors who gave 3284 transfusable components, and it was possible to evaluate 1245 recipients, totaling 6495 person-years of observation. The mean observation period per recipient was 5.5 years with a maximum of 51 years. No case of CJD or prion disease was reported among the recipient population.
The study suggests that CJD may not be transfusion-transmissible, a position in agreement with similar findings from two similar European reports amounting to an overall observation period of 15,500 person-years. These studies have supported the conclusion that the risk, if any, of transmission of CJD by blood products is extremely small and remains theoretical.
多年来,人们一直担心通过输血传播经典型克雅氏病(CJD)的风险,尤其是在认识到变异型克雅氏病(vCJD)可通过这种方式传播之后。我们报告了一项对随后发生 CJD 的供体献血者的 28 年回顾性研究。
确定了确诊为 CJD 且有献血史的患者。要求血液中心提供关于献血分布的信息,并要求收货人提供关于献血接受者的信息。确定了每个可获得的接受者的存活状况,如果死亡,则主要从国家死亡指数中获得报告的死亡原因。所有纳入研究数据库的接受者都在最后一次记录的存活状况审查之前贡献了个人时间。
有 84 名符合条件的供体捐献了 3284 份可输血成分,可评估 1245 名接受者,总计 6495 人年的观察时间。每位接受者的平均观察期为 5.5 年,最长为 51 年。在接受者人群中未报告任何 CJD 或朊病毒病病例。
该研究表明 CJD 可能不会通过输血传播,这一立场与来自两个类似的欧洲报告的类似发现一致,总观察期为 15500 人年。这些研究支持了这样的结论,即如果存在通过血液制品传播 CJD 的风险,也是极小的,仍然是理论上的。